BioSpace News Archive

Nature Medicine Publishes Two Studies Highlighting Signatera’s Clinical Utility in Patients with Gastrointestinal Malignancies.

Cyprium Partners is pleased to announce it has completed its 100 th platform investment, providing debt and equity to OneroRx Inc, headquartered in West Des Moines, Iowa.

InflaRx Pharmaceuticals Inc. announced today that the Company has launched The InflaRx Commitment Program (Commitment Program).

FibroBiologics, Inc., a clinical-stage biotechnology company focused on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced that it has been notified by NASDAQ that trading of its common stock will commence on Wednesday, January 31, 2024.

JCR Pharmaceuticals Co., Ltd. announced today that it will present six presentations at the 20th Annual WORLD Symposium ™ 2024, to be held February 4-9, 2024 in San Diego, Calif.

Domain to receive a grant over a five year period to support DT-7012 which is expected to start a Phase I study by mid-2025.

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) (“Reviva” or the “Company”) today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva, will participate in a fireside chat moderated by Jim Molloy, Senior Analyst at Alliance Global Partners, at the Lytham Partners 2024 Investor Select Conference.

The American Liver Foundation announced ten new liver research awards that will fund early career scientists working in basic and translational liver disease research.

Third Rock Ventures announced today that it has expanded its senior team with the addition and promotion of several industry leaders.

AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its fourth quarter and full year 2023 financial results on Thursday, February 15, 2024.